ELITE PHARMACEUTICALS INC /NV/
ELTP · OTCMCIK 1053369fmd_1J1J7TDHRBDDFMQ7HAEC0E1YVRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 7 | 8 | 18 | 25 | 32 | 34 | 57 | 84 | 149 |
| Cost of revenue | 6 | 4 | 5 | 10 | 14 | 17 | 18 | 30 | 44 | 74 |
| Gross profit | 4 | 4 | 3 | 8 | 12 | 15 | 17 | 26 | 40 | 75 |
| Research and development | 8 | 10 | 8 | 6 | 5 | 4 | 6 | 7 | 8 | 6 |
| Net interest income after provision | – | – | – | (0) | 1 | 1 | – | – | – | – |
| Total operating expenses | 11 | 13 | 12 | 10 | 10 | 10 | 13 | 16 | 20 | 26 |
| Operating income | (7) | (9) | (9) | (2) | 2 | 5 | 4 | 11 | 20 | 49 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 9 | 4 | (1) | 0 | 2 | 1 | 0 | (10) | (20) | 8 |
| Income before taxes | 2 | (5) | (10) | (2) | 4 | 6 | 4 | 0 | (0) | 57 |
| Income tax expense | (2) | (1) | (1) | – | – | (2) | 0 | (20) | 4 | 12 |
| Net income from continuing operations | 4 | (4) | (9) | – | – | 8 | 4 | 20 | (4) | 45 |
| Net income | 4 | (4) | (9) | (2) | 5 | 9 | 4 | 20 | (4) | 45 |
| Net income to common shareholders | 25 | (4) | (9) | (2) | 5 | 9 | 4 | 20 | (4) | 45 |